AzTrials
AzTrials

QT ProlongationERASNCT05759260

QT Interval in Athletes

An observational study of QT Prolongation, run by Istituto Auxologico Italiano at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

QT interval prolongation occurs in athletes and causes concerns, as it may indicate the life-threatening long QT syndrome (LQTS). Clinical and genetic testing identify those clearly affected by LQTS but in many no disease-causing mutations are found and diagnosis remains uncertain while they are barred from… Read more about this study

Who is it for?
Any age
Conditions the study is for
QT Prolongation
What is being tested?
Observation
How many people
869 participants
Where
1 siteItaly
Study dates
5 Dec 2018to 4 Apr 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Child, Adult, Older adult

Study population: Athletes

Who may be able to join

  • Athletes
  • QTc interval > 450 msec (cases) or < 430 msec (controls)

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Istituto Auxologico Italiano - Center for Cardiac Arrhythmias of Genetic Origin

    Milan, 20135

Other trials in Italy

About this study

Official title: Does Exercise Training Mostly Unmask Congenital Long QT Syndrome or Simply Reveals a Novel Form of Acquired Long QT Syndrome in Genetically Predisposed Youngsters Practicing Sports?

QT interval prolongation occurs in athletes and causes concerns, as it may indicate the life-threatening long QT syndrome (LQTS). Clinical and genetic testing identify those clearly affected by LQTS but in many no disease-causing mutations are found and diagnosis remains uncertain while they are barred from competitive sports. The investigators hypothesize that several cases represent an acquired form of LQTS, akin to drug-induced LQTS, caused by exercise training acting as a trigger or "second hit" on a genetic predisposition. The investigators will use next generation sequencing to screen major and minor LQTS genes plus common and rare variants modulating the QT interval in athletes with a QTc>450ms (cases) and in those with a QTc<430ms (controls). Thus, the investigators will quantify the presence of LQTS in athletes and will also focus on those who normalize their QTc after detraining, as this points to activation of stretch-receptors. The investigators will clarify QT prolongation in athletes and contribute to correct diagnosis.

Read the detailed description

Background - In Italy, by law, long QT syndrome (LQTS) precludes sport participation. The Center for Cardiac Arrhythmias of Genetic Origin - Istituto Auxologico Italiano serves as referral center for sport cardiologists who certify that youngsters can practice competitive sports. Among athletes, QT interval prolongation has been frequently reported but its prevalence varies greatly from 3/1,000 to 6% based on surface ECG without genetic studies. Indeed, the presence of LQTS-causing mutations has never been quantified. Furthermore, whether this observed QT prolongation is related to training or to a latent form of LQTS has never been established. This has impacted on athlete-specific ECG criteria guidelines to distinguish between physiological or pathological values. The investigators hypothesize that QT prolongation may be an expression of "acquired" LQTS in which exercise may unmask a genetic predisposition, similar to what drugs do in drug-induced LQTS. This is supported by the investigators' observation that, following detraining, a relevant number of youngsters, all mutation-negative, normalize their QT interval. This raises the possibility that this "training-induced" QT prolongation could represent a genetic predisposition related to the activation of myocardial stretch receptors which would increase the inward calcium current and thereby prolong action potential duration. This would manifest itself as a prolongation of the QT interval on the ECG and would imply a training-induced reversible phenomenon. If recognized, this would avoid many incorrect diagnoses of LQTS.

Hypothesis and Specific Aims - Three hypotheses constitute the investigators main one, namely that QT prolongation in athletes may represent genetic variability modulated by exercise and not evidence of congenital LQTS.

The first hypothesis relates to the occurrence of prolonged QT intervals among athletes: often just a borderline prolongation but sometimes so significant to suggest LQTS. As LQTS is characterized by life-threatening arrhythmias triggered by physical or psychological stress, a correct diagnosis when dealing with youngsters practicing competitive sports is imperative. Quantification is needed and this requires genetic testing because QT prolongation in athletes cannot be automatically equated to LQTS. Among young athletes with QT prolongation the investigators expect to find both genotype-negative and genotype-positive individuals, the latter even among those with borderline QT prolongation. The results will allow to quantify the prevalence of LQTS mutation carriers (MCs) among young athletes and this early diagnosis will protect them from life-threatening arrhythmias. Sport physicians will thus be alerted to the importance of measuring the QT interval.

The investigators' second hypothesis is that, similar to drug-induced LQTS, rare or common functional variants in LQTS-associated genes may predispose to QT interval prolongation following exercise training. These variants confer either a clearly pathological (congenital) or a subclinical (exercise-induced) susceptibility. Drug-induced QT prolongation manifests itself in just a few susceptible patients receiving an IKr blocking drug. Similarly, exercise training could unmask this propensity either in "silent mutation carriers", i.e. true LQTS patients manifesting the disease only with a trigger such as exercise, or in individuals with a genetically-determined susceptibility to increase QT interval duration that needs a second-hit to manifest but which can be completely reversed once the trigger is eliminated. The third hypothesis, tightly related to the second, originates from the investigators' repeated observations of cases sharing the following features: marked QT prolongation strongly suggesting LQTS, no personal nor family history of arrhythmic events, mutation-negative, and QTc normalization after 6 or more months of detraining. The pattern is very consistent and clearly not a chance event.

Normalization following detraining suggests that prolongation was caused by training. The investigators posit that this phenomenon is due to a genetic predisposition. During exercise training the heart is exposed to substantial mechanical stress, i.e. application of forces with shear, pressure and stretch components, and responds with mechanosensitive modulation of its main regulatory processes. Mechano-sensitivity of heart rhythm, or mechano-electric feedback, is orchestrated by diverse types of stretch-activated ion channels. Among them, voltage-gated cation selective channels that normally conduct the main ionic currents determining QT duration, such as ICaL and INa. Repeated exercise is expected to initiate a mechano-electric feedback loop resulting in a reflex increase in the release of intracellular calcium which, in turn, by prolonging the plateau phase of the action potential will prolong the QT interval on the surface ECG. These effects can explain the phenomenon of transient and reversible QT prolongation which, by occurring in just a few athletes, strongly suggests a genetic predisposition. This hypothesis implies that these youngsters will no longer be labeled as "affected by LQTS"; there will be novel insights on the role of the stretch-activated channels and, a mechanistic explanation would be provided for a puzzling clinical phenomenon.

Conditions
QT Prolongation
Being tested
Observation
Keywords
QT interval, Genetics, Long QT syndrome
Medical subject headings
Long QT Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ObservationOther

    Observation

Study groups in NCT05759260
Study groupRoleWhat they receive
CasesAthletes with QT interval prolongation
Receives: Other: Observation
ControlsAthletes without QT interval prolongation
Receives: Other: Observation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Genetic differences

    Quantification of MCs and non-mutation carriers (NMCs) among the young athletes with a QTc> 450 ms to define the LQTS prevalence in athletes and to identify an adequate cut-off for likely pathological QTc prolongation in athletes.

    Measured: At enrolment

Secondary outcomes (1)
  1. Predisposition to QT prolongation

    Identification of genetic variants associated with predisposition to prolong the QT interval following exercise training.

    Measured: At enrolment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Mar 2023
  2. Study start5 Dec 2018
  3. Primary completion4 Apr 2023
  4. Study completion4 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
869 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05759260
Sponsor's protocol ID
26M621
Acronym
ERAS
Status last verified
Sep 2023
First submitted
21 Feb 2023
Last updated
29 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J. 2013 Oct;34(40):3109-16. doi: 10.1093/eurheartj/eht089. Epub 2013 Mar 18.

    PubMed 23509228
  • Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V, Hayashi K, Nakajima T, Ohno S, Makiyama T, Wu J, Hasegawa K, Mastantuono E, Dagradi F, Pedrazzini M, Yamagishi M, Berthet M, Murakami Y, Shimizu W, Guicheney P, Schwartz PJ, Horie M. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J. 2016 May 7;37(18):1456-64. doi: 10.1093/eurheartj/ehv695. Epub 2015 Dec 28.

    PubMed 26715165
  • Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016 Apr 5;67(13):1639-1650. doi: 10.1016/j.jacc.2015.12.063.

    PubMed 27150690
  • Peyronnet R, Nerbonne JM, Kohl P. Cardiac Mechano-Gated Ion Channels and Arrhythmias. Circ Res. 2016 Jan 22;118(2):311-29. doi: 10.1161/CIRCRESAHA.115.305043.

    PubMed 26838316

Questions about this trial

What is this clinical trial studying?

An observational study of QT Prolongation, run by Istituto Auxologico Italiano at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Genetic differences (time frame: At enrolment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05759260, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2023; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in